3D Communications Expands Market Access and Reimbursement Communications Services for Pharmaceutical Companies

May 6, 2015-- 3D Communications announced today that it has significantly expanded its process for helping pharmaceutical companies communicate the value of their drugs and maximize patient access.
The newly expanded 3D Market Access and Reimbursement Communications services will go beyond helping companies develop and deliver their "Value Story".  It will also provide a process to identify and engage critical stakeholders earlier in the "innovation-to-market" timeline, and incorporate critical learnings throughout the development process.   
"Getting FDA approval used to be the major obstacle pharmaceutical companies had to overcome to get a drug to market," said 3D Founding Partner, Cindy DiBiasi.  "Today, companies must also demonstrate a drug's value to multiple audiences in order to justify pricing and maximize its reimbursement and access to patients. Without proving that value, patients, the healthcare system, and pharmaceutical companies all lose." 
To lead the newly-enhanced team of market access, communications, science, and stakeholder experts, 3D has hired Jane Horvath. Previously, Jane was the Executive Director of Health Policy and Reimbursement at Merck & Co. and a Vice President at Breakaway Policy Strategies. 
"Global pharmaceutical markets are undergoing a seismic shift," said Horvath.  "Because of that, the old way of thinking about how to price a drug and talk about its value doesn't work anymore.  I'm excited about this opportunity at 3D, because the process allows us to assess what's important to patients, physicians, and payers and help pharmaceutical companies integrate and communicate the value of their products in terms of how patients feel, function and/or live."
3D's Market Access and Reimbursement Communications program has been built on the company's proprietary 3D ACT® (Analysis, Content Development, Testing) process, which has helped companies win approval at FDA Advisory Committee meetings for more than a decade.
"We're excited to have Jane on our team because she understands pharma, the issues, and the environment – and she is extremely forward-thinking, said DiBiasi. "Jane's expertise, combined with our 3D ACT® process, will help our clients succeed in this new Market Access reality."
In addition to her work in pharma, Jane held a series of high-profile government positions including Deputy Assistant Secretary for Legislation in the US Department of Health and Human Services where she was responsible for legislative policy for all health-related areas, including Medicare, Medicaid, and prescription drug pricing.
--##--
3D Communications is a strategic communications firm that prepares companies for high-stakes regulatory presentations, meetings, and media interviews. Our expertise lies in transforming highly complex information into clear and persuasive communications. 3D's team of seasoned experts use a proven process, based on innovative, proprietary tools, to help companies succeed. Our services include strategic analysis, messaging, content development, speaker and media training, crisis management, and preparation for early and late-stage regulatory communications. For more information, visit www.3Dcommunications.us  Follow us on Twitter @3D_Comm (@3D_Comm)

Suggested Articles

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.